Q1 Earnings Beat: Social media erupted with discussion following Medline's release of strong first-quarter results, featuring net sales of $7.4 billion, a 10.7% year-over-year increase that beat expectations. The company raised its full-year organic sales growth outlook to 8.5%-9.5%, signaling confidence in ongoing customer wins and expansions.
Margin Pressures Emerge: Despite top-line strength, users pointed to declining profitability, with adjusted EBITDA down 11% and net income falling 26% due to tariffs, higher costs, and IPO-related expenses. Tariffs alone impacted costs by $85 million, sparking debates on the sustainability of aggressive growth investments. Cash flow concerns also surfaced amid rising working capital needs.
Strategic Optimism Persists: Conversations praised Medline's unique hybrid model spanning manufacturing to supply chain solutions in medical essentials, bolstered by automation partnerships. Technical analysts spotted bullish RSI divergences, eyeing potential upside amid the stock's post-IPO trajectory. Overall, the tone reflects balanced views on growth versus near-term hurdles.
Note: This discussion summary was generated from an AI condensation of post data.
Medline Insider Trading Activity
Medline insiders have traded $MDLN stock on the open market 28 times in the past 6 months. Of those trades, 4 have been purchases and 24 have been sales.
Here’s a breakdown of recent trading of $MDLN stock by insiders over the last 6 months:
- GROUP INC. CARLYLE has made 0 purchases and 2 sales selling 45,242,173 shares for an estimated $1,625,293,097.
- MOZART COINVESTMENT HOLDINGS, L.P. CARLYLE has made 0 purchases and 2 sales selling 45,242,173 shares for an estimated $1,625,293,097.
- & FRIEDMAN CAPITAL PARTNERS X (PARALLEL), L.P. HELLMAN has made 0 purchases and 7 sales selling 32,219,608 shares for an estimated $1,231,240,883.
- 8 HOLDINGS MOZART MANAGER L.L.C. BCP has made 0 purchases and 4 sales selling 27,852,986 shares for an estimated $1,128,268,756.
- MOZART ML-2 HOLDCO L.P. BX has made 0 purchases and 4 sales selling 27,852,986 shares for an estimated $1,128,268,756.
- GROUP CAYMAN INVESTMENT HOLDINGS, L.P. TC sold 26,105,840 shares for an estimated $1,070,339,440
- CIRCLE ML HOLDCO GP, LLC CP sold 26,105,840 shares for an estimated $1,070,339,440
- PRIVATE LTD GIC has made 1 purchase buying 12,586,206 shares for an estimated $364,999,974 and 1 sale selling 10,204,351 shares for an estimated $289,480,090.
- GROUP VII S1, L.L.C. TC sold 19,136,333 shares for an estimated $554,953,657
- AGGREGATOR II LP MOZART sold 13,462,600 shares for an estimated $381,911,075
- ANDREW J. MILLS purchased 2,586,206 shares for an estimated $74,999,974
- CHARLES N. MILLS has made 2 purchases buying 2,579,310 shares for an estimated $74,799,990 and 0 sales.
To track insider transactions, check out Quiver Quantitative's insider trading dashboard. You can access data on insider stock transactions through the Quiver Quantitative API.
Medline Hedge Fund Activity
We have seen 229 institutional investors add shares of Medline stock to their portfolio, and 13 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- CARLYLE GROUP INC. added 215,303,036 shares (+inf%) to their portfolio in Q4 2025, for an estimated $9,042,727,512
- H&F CORPORATE INVESTORS X, LTD. added 99,514,069 shares (+inf%) to their portfolio in Q4 2025, for an estimated $4,179,590,898
- FMR LLC added 26,354,214 shares (+inf%) to their portfolio in Q4 2025, for an estimated $1,106,876,988
- VANGUARD GROUP INC added 18,887,568 shares (+inf%) to their portfolio in Q4 2025, for an estimated $793,277,856
- MORGAN STANLEY added 15,162,060 shares (+inf%) to their portfolio in Q4 2025, for an estimated $636,806,520
- CAPITAL RESEARCH GLOBAL INVESTORS added 14,784,203 shares (+inf%) to their portfolio in Q4 2025, for an estimated $620,936,526
- LONE PINE CAPITAL LLC added 11,716,697 shares (+inf%) to their portfolio in Q4 2025, for an estimated $492,101,274
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard. You can access data on hedge funds moves and 13F filings through the Quiver Quantitative API.
Medline Analyst Ratings
Wall Street analysts have issued reports on $MDLN in the last several months. We have seen 6 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- BTIG issued a "Buy" rating on 01/12/2026
- RBC Capital issued a "Outperform" rating on 01/12/2026
- Bernstein issued a "Outperform" rating on 01/12/2026
- Wolfe Research issued a "Outperform" rating on 01/12/2026
- Barclays issued a "Overweight" rating on 01/12/2026
- Citigroup issued a "Buy" rating on 01/12/2026
To track analyst ratings and price targets for Medline, check out Quiver Quantitative's $MDLN forecast page.
Medline Price Targets
Multiple analysts have issued price targets for $MDLN recently. We have seen 23 analysts offer price targets for $MDLN in the last 6 months, with a median target of $50.0.
Here are some recent targets:
- Patrick Donnelly from Citigroup set a target price of $60.0 on 03/11/2026
- Lisa Gill from JP Morgan set a target price of $53.0 on 03/10/2026
- David Larsen from BTIG set a target price of $55.0 on 03/09/2026
- Ivan Feinseth from Tigress Financial set a target price of $60.0 on 03/09/2026
- Patrick Wood from Morgan Stanley set a target price of $52.0 on 03/02/2026
- Stephen Baxter from Wells Fargo set a target price of $47.0 on 02/27/2026
- Ryan Halsted from RBC Capital set a target price of $53.0 on 02/26/2026
This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.
